Healthcare provider profile · identity verified

Charles Effiong, MD

Internal Medicine · CHARLESTON, SC · NPI 1487604757

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	711	263
Atorvastatin Calcium	Atorvastatin Calcium	358	135
Lisinopril	Lisinopril	268	99
Pravastatin Sodium	Pravastatin Sodium	218	81
Jardiance	Empagliflozin	203	60
Omeprazole	Omeprazole	198	68
Metformin Hcl	Metformin Hcl	191	74
Albuterol Sulfate Hfa	Albuterol Sulfate	182	57
Gabapentin	Gabapentin	158	58
Alendronate Sodium	Alendronate Sodium	135	52
Hydrochlorothiazide	Hydrochlorothiazide	126	48
Atenolol	Atenolol	111	41
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	110	33
Tramadol Hcl	Tramadol Hcl	106	32
Trazodone Hcl	Trazodone Hcl	98	26
Trulicity	Dulaglutide	97	27
Simvastatin	Simvastatin	96	30
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	95	37
Furosemide	Furosemide	91	36
Losartan Potassium	Losartan Potassium	88	36
Metoprolol Tartrate	Metoprolol Tartrate	79	29
Farxiga	Dapagliflozin Propanediol	77	19
Glipizide	Glipizide	76	30
Levothyroxine Sodium	Levothyroxine Sodium	71	26
Ozempic	Semaglutide	70	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	65	27
Citalopram Hbr	Citalopram Hydrobromide	61	16
Naproxen	Naproxen	58	26
Metoprolol Succinate	Metoprolol Succinate	55	26
Sertraline Hcl	Sertraline Hcl	52	17
Carvedilol	Carvedilol	51	29
Tamsulosin Hcl	Tamsulosin Hcl	50	21
Fluticasone Propionate	Fluticasone Propionate	49	25
Meloxicam	Meloxicam	49	21
Metformin Hcl Er	Metformin Hcl	48	23
Clopidogrel	Clopidogrel Bisulfate	47	13
Pregabalin	Pregabalin	47	20
Zolpidem Tartrate	Zolpidem Tartrate	46	11
Amitriptyline Hcl	Amitriptyline Hcl	45	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	20
Pantoprazole Sodium	Pantoprazole Sodium	44	14
Spironolactone	Spironolactone	43	21
Ibuprofen	Ibuprofen	40	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	40	14
Allopurinol	Allopurinol	39	13
Eliquis	Apixaban	38	18
Tizanidine Hcl	Tizanidine Hcl	38	12
Alprazolam	Alprazolam	36	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	35	16
Vitamin D2	Ergocalciferol (Vitamin D2)	35	16
Triamcinolone Acetonide	Triamcinolone Acetonide	34	18
Doxazosin Mesylate	Doxazosin Mesylate	31	13
Januvia	Sitagliptin Phosphate	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	11
Hydroxyzine Hcl	Hydroxyzine Hcl	30	14
Lovastatin	Lovastatin	30	12
Colchicine	Colchicine	29	suppressed
Famotidine	Famotidine	29	15
Valsartan	Valsartan	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	12
Potassium Chloride	Potassium Chloride	23	suppressed
Clonazepam	Clonazepam	22	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	22	14
Calcitriol	Calcitriol	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	11
Nifedipine Er	Nifedipine	21	suppressed
Prednisone	Prednisone	21	11
Xarelto	Rivaroxaban	21	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Doxepin Hcl	Doxepin Hcl	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	17	suppressed
Indapamide	Indapamide	17	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Glipizide Er	Glipizide	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Cyproheptadine Hcl	Cyproheptadine Hcl	15	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Risperidone	Risperidone	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Fluconazole	Fluconazole	14	12
Myrbetriq	Mirabegron	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Techlite Pen Needle	Pen Needle, Diabetic	13	suppressed
Clonidine	Clonidine	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Etodolac	Etodolac	12	suppressed
Jantoven	Warfarin Sodium	12	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error